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Doxorubicin is an anthracycline drug used as frontline che-
motherapy of osteosarcoma among other types of cancers.
While quite effective in providing a good control over the
tumours in some patients, it can cause significant toxicity to
organs such as the heart [1]. Attempts to ameliorate this tox-
icity with agents such as dexrazoxane have been successful,
but not without complications [2] as will be discussed in this
talk. Pigment epithelium-derived factor (PEDF), a potent anti-
angiogenic and osteogenetic protein [3], was used to reduce
this side-effect, together with an analysis of levels of adenosine
triphosphate (ATP) and reactive oxygen species (ROS). The
effects of low dose doxorubicin in a clinically relevant dosing
model will be discussed.
Acknowledgements
The author acknowledges the support of a Curtin Academic
50 scheme and various members of his lab for data generated.
* E-mail address: Crispin.Dass@curtin.edu.au.
Peer review under responsibility of Shenyang Pharmaceutical University.
http://dx.doi.org/10.1016/j.ajps.2015.10.016
1818-0876/© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 2 2 – 2 3
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
HOSTED BY
ScienceDirect
R E F E R E N C E S
[1] Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on
anticancer molecular action, toxicity and novel drug delivery
systems. J Pharm Pharmacol 2013;65:157–170.
[2] Bryant J, Picot J, Levitt G, et al. Cardioprotection against the
toxic effects of anthracyclines given to children with
cancer: a systematic review. Health Technol Assess 2007;11:1–
84.
[3] Alcantara MB, Nemazannikova N, Elahy M, et al. Pigment
epithelium-derived factor upregulates collagen I and
downregulates matrix metalloproteinase 2 in osteosarcoma
cells, and colocalises to collagen I and heat shock protein 47
in fetal and adult bone. J Pharm Pharmacol 2014;66:1586–
1592.
Fig. 1 PEDF reduces extent of doxorubicin-induced cellular vacuolation in cardiomyocytes.
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